Notice of appeal
Released
Released
Announcement PDF
ASX Announcement
NOTICE OF APPEAL
15 January 2026, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma)
refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October
2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its
announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette
Pharmaceuticals, Inc. (Cosette) and its BidCo.
Mayne Pharma has today received a notice of appeal filed by Cosette and its BidCo with the
Supreme Court of New South Wales, Court of Appeal.
The two grounds set out in the notice of appeal seek to challenge various of the Court’s findings
related to:
1. Mayne Pharma’s FY25 EBITDA the subject of Cosette’s misleading and deceptive conduct
claim; and
2. Cosette’s allegation that a Mayne Material Adverse Change had occurred on the basis of
Cosette’s pleaded Q3 FY25 Sales Performance Matters.
Mayne Pharma is considering the notice of appeal and intends to vigorously defend the appeal.
- ENDS –
Authorised for release to the ASX by the Board Chair
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health and also provides contract development
and manufacturing services to clients worldwide. Mayne Pharma has a 40 year track record of
innovation and success in developing new oral drug delivery systems. These technologies have
been successfully commercialised in numerous products that continue to be marketed around
the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Share your feedback
Discover